10-Q: Kaya Holdings Reports Mixed Q2 Results Amidst Psilocybin Pivot

Kaya Holdings reports a net income of $432,210 for the quarter ending June 30, 2024, primarily due to derivative liabilities, while transitioning from cannabis to psilocybin operations.

Summary

• Kaya Holdings, Inc. reported a net income of $432,210 for the three months ended June 30, 2024, a significant turnaround from a net loss of $714,156 in the same period last year.
• The company's revenue decreased to $0 for the quarter, down from $55,116 in the prior year, due to the closure of its Oregon cannabis retail operations.
• For the six months ended June 30, 2024, the company's revenue was $28,009, compared to $103,361 in the same period of 2023.
• The company's operating expenses were $399,236 for the quarter, compared to $348,712 in the same period last year.
• The company's net loss for the six months ended June 30, 2024 was $607,600, compared to a net loss of $665,609 for the same period in 2023.
• The company's cash position increased to $61,282 as of June 30, 2024, with a working capital deficit of $7,701,014.
• The company is transitioning from cannabis to psilocybin operations, having received a license for its 'The Sacred Mushroom' psilocybin treatment center in Portland, Oregon.
• The company has raised capital through convertible notes and private placements to fund its psilocybin business and international projects.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company achieved a net income for the quarter, it also faces significant challenges, including a working capital deficit, ineffective internal controls, and a dependence on capital raises. The transition to psilocybin is a positive development, but the company's financial health remains precarious.

Positives

• The company achieved a net income of $432,210 for the quarter ending June 30, 2024, a substantial improvement from the previous year.
• The company successfully obtained a license for its psilocybin treatment center, 'The Sacred Mushroom', marking a significant milestone in its strategic shift.
• The company has secured additional funding through private placements and convertible notes, supporting its growth plans.
• The company is positioned as a first mover in the emerging US psychedelic therapeutics industry.
• The company has a plan of operations and believes it can meet its future liquidity needs.

Negatives

• The company's revenue decreased to $0 for the quarter due to the closure of its Oregon cannabis retail operations.
• The company has a significant working capital deficit of $7,701,014.
• The company's internal controls over financial reporting were deemed ineffective as of June 30, 2024.
• The company is dependent on its ability to raise capital.
• The company has incurred net losses for the six months ended June 30, 2024 and 2023.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise capital.
• The company's internal controls over financial reporting are not effective, which could lead to misstatements in financial reports.
• The company faces significant competition in both the cannabis and psychedelic medicine sectors.
• The company's operations are subject to regulatory risks, including the evolving legal landscape for cannabis and psilocybin.
• The company's foreign operations are subject to comparable government regulation in Greece and other jurisdictions.
• The company's plan of operations may not result in generating positive working capital in the near future.

Future Outlook

Management believes that further proceeds from financing transactions, combined with existing and anticipated revenues, will alleviate the company's financial difficulties and allow it to meet its working capital needs for a period of between twelve and eighteen months. However, there is no assurance that further funding will be achieved or that the company will not require additional financing sooner.

Management Comments

• Management believes that further proceeds expected to be received from financing transactions that it is seeking to enter into, combined with existing and anticipated revenues, will alleviate the Companys financial difficulties to a significant extent.
• Management plans include the sale of additional equity and debt securities, alliances and/or partnerships, business transactions, and development of a unified brand.

Industry Context

The company is pivoting from the cannabis sector to the emerging psilocybin therapeutics market, which is gaining traction with regulatory changes and growing interest in mental health treatments. The company is positioning itself to be a first mover in this market, leveraging its experience in Oregon's regulated cannabis industry.

Comparison to Industry Standards

• The company's transition to psilocybin treatment centers aligns with the growing trend of exploring psychedelic therapies for mental health, similar to companies like Compass Pathways, ATAI Life Sciences, and Cybin, which are developing synthetic versions of psilocybin.
• The company's approach to offering a superior treatment experience at a lower price point is a competitive strategy in the emerging psilocybin market, where prices for treatments can vary widely.
• The company's focus on the 'set and setting' for psilocybin journeys is consistent with industry best practices, emphasizing the importance of a safe and comfortable environment for effective treatment.
• The company's international expansion into Greece for cannabis operations is a common strategy for companies seeking to capitalize on favorable regulations and market opportunities in Europe.

Legal Proceedings

• The company was involved in a lawsuit with Law Offices of Ross Day, which was resolved with the company waiving an arbitration award.
• The company is involved in a lawsuit with P3 Distributing LLC for unpaid vendor invoices.

Related Party Transactions

• The company has related party loans payable to a stockholder.
• The company has accrued compensation due to Tudog International Consulting, Inc. and BMN Consultants, Inc.

Stakeholder Impact

• Shareholders face risks due to the company's financial instability and dependence on capital raises.
• Employees are impacted by the company's transition and potential changes in operations.
• Customers of the psilocybin treatment center will benefit from the new services.
• Creditors are exposed to risks due to the company's financial difficulties.

Next Steps

• The company plans to develop its planned Oregon psilocybin business.
• The company plans to develop its international projects in Greece.
• The company will continue to seek financing to support its operations.
• The company will work to improve its internal controls over financial reporting.

Key Dates

Keywords

psilocybin, psychedelic treatment, cannabis, Oregon, Kaya Holdings, financial results, convertible debt, The Sacred Mushroom, mental health, derivative liabilities